Premium
Safety profile of amisulpride in short‐ and long‐term use
Author(s) -
Rein W.,
Coulouvrat C.,
DondeyNouvel L.
Publication year - 2000
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.0065-1591.2000.007s021[dash]5.x
Subject(s) - amisulpride , akathisia , risperidone , haloperidol , antipsychotic , atypical antipsychotic , psychology , schizophrenia (object oriented programming) , adverse effect , medicine , olanzapine , psychiatry , placebo , dopamine , alternative medicine , pathology
Objective: To assess the safety of the new atypical antipsychotic drug, amisulpride, in short‐ and long‐term use. Method: Studies comparing the safety of amisulpride with that of haloperidol and risperidone, respectively, are reviewed. Safety was monitored by open adverse event reporting, the Simpson‐Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale. Results: In short‐ and long‐term studies, amisulpride induced significantly less EPS and akathisia than haloperidol. Safety ratings were similar to risperidone in short‐term studies. In studies of chronic schizophrenia with predominant negative symptoms, amisulpridewas similar to placebo. Endocrine effects were similar inamisulpride‐, haloperidol‐ and risperidone‐treated patients. Weight gain with amisulpride was significantly less than risperidone in a short‐term study. No clinically important effects on haematological, hepatic or cardiac function were recorded. Data obtained in short‐ and long‐term studies have been confirmed in extensive post‐marketing surveillance data. Conclusion: Amisulpride has a broad spectrum of efficacy in schizophrenia without introducing the iatrogenic consequences associated with older therapies.